GW Pharmaceuticals Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals in the last year. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
View analyst ratings for GW Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given GW Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GW Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

GW Pharmaceuticals saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 597,600 shares, a decrease of 66.0% from the January 28th total of 1,760,000 shares. Based on an average daily volume of 806,000 shares, the days-to-cover ratio is presently 0.7 days.
View GW Pharmaceuticals' Short Interest.

GW Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for GW Pharmaceuticals.

GW Pharmaceuticals plc (NASDAQ:GWPH) posted its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company had revenue of $137.10 million for the quarter, compared to the consensus estimate of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. The firm's revenue was up 50.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS.
View GW Pharmaceuticals' earnings history.

GW Pharmaceuticals' stock was trading at $86.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GWPH stock has increased by 147.4% and is now trading at $214.94.
View which stocks have been most impacted by COVID-19.

14 analysts have issued 12-month price objectives for GW Pharmaceuticals' shares. Their forecasts range from $128.00 to $275.00. On average, they anticipate GW Pharmaceuticals' stock price to reach $197.75 in the next twelve months. This suggests that the stock has a possible downside of 8.0%.
View analysts' price targets for GW Pharmaceuticals or view top-rated stocks among Wall Street analysts.

14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees.

Some companies that are related to GW Pharmaceuticals include Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), UCB (UCBJF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), CureVac (CVAC), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Bausch Health Companies (BHC) and Teva Pharmaceutical Industries (TEVA).
View all of GWPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (6.36%), Morgan Stanley (2.74%), Federated Hermes Inc. (2.33%), ETF Managers Group LLC (2.00%), M&G Investment Management Ltd. (1.65%) and Price T Rowe Associates Inc. MD (1.64%). Company insiders that own GW Pharmaceuticals stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
View institutional ownership trends for GW Pharmaceuticals.

GWPH stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Victory Capital Management Inc., Clough Capital Partners L P, Janus Henderson Group PLC, Hardman Johnston Global Advisors LLC, Baker BROS. Advisors LP, M&G Investment Management Ltd., and BlackRock Inc.. Company insiders that have sold GW Pharmaceuticals company stock in the last year include Adam D George, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, and Volker Knappertz.
View insider buying and selling activity for GW Pharmaceuticals or view top insider-selling stocks.

GWPH stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Renaissance Technologies LLC, Brown Capital Management LLC, Tri Locum Partners LP, Price T Rowe Associates Inc. MD, Jennison Associates LLC, Penserra Capital Management LLC, and Candriam Luxembourg S.C.A..
View insider buying and selling activity for GW Pharmaceuticals or or view top insider-buying stocks.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GWPH stock can currently be purchased for approximately $214.94.

GW Pharmaceuticals has a market capitalization of $6.67 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

GW Pharmaceuticals employs 901 workers across the globe.

The official website for GW Pharmaceuticals is www.gwpharm.com.

GW Pharmaceuticals is headquartered at SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ.

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]